Summit Therapeutics Inc.
SMMTHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSummit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Valued at $11.53B, SMMT is a large-cap name in its sector. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Market Cap
$11.53B
Beta
-1.25
P/E (TTM)
—
P/E (Fwd)
-12.54
EPS (TTM)
$-1.59
EPS (Fwd)
$-1.19
ROE
-270.9%
ROA
-148.2%
Cash
$598.7M
Total Debt
$20.0M
Free CF
$69.9M
52W Change
-24.0%
Annual Financials
Cash vs Debt
Summit Therapeutics Inc. holds $598.7M in cash against $20.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $69.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -270.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $705K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Summit Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, SMMT has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SMMT.